Today: 10 July 2026
Browse Category

NASDAQ:BKYI 27 October 2025 - 28 January 2026

BIO-key (BKYI) spikes on major Middle East defense biometric deployment — stock reacts as company expands EMEA footprint [Nov. 7, 2025]

BIO-key (BKYI) spikes on major Middle East defense biometric deployment — stock reacts as company expands EMEA footprint [Nov. 7, 2025]

BIO‑key International, Inc. said today it has secured a “significant” new identity and biometric security deployment with a major defense‑sector security organization in the Middle East, a win the company calls one of its largest security‑sector deployments in the region to date. The unnamed customer selected BIO‑key to protect critical infrastructure and sensitive access environments using the company’s biometric‑centric, multi‑factor authentication stack; financial terms were not disclosed. The project is being delivered with Cloud Distribution, a Saudi‑based value‑added distributor that BIO‑key partnered with this year. GlobeNewswire
7 November 2025
··
BIO-key (BKYI) Stock Jumps as Nordic Deal and New Biometric Tech Fuel Investor Buzz

BIO-key (BKYI) Stock Jumps as Nordic Deal and New Biometric Tech Fuel Investor Buzz

BIO-key’s stock has seen renewed action in late October. After languishing for much of the year, BKYI shares rallied on a string of positive developments. The stock closed at $0.77 on Friday, Oct. 24 trading212.com and has risen in 7 of the past 10 sessions stockinvest.us. Over the last two weeks the price is up about 8.5% stockinvest.us, a notable bump for the thinly traded micro-cap. Trading volume, while modest, has ticked up alongside the price – a positive technical sign in the eyes of analysts stockinvest.us.
27 October 2025
·

Stock Market Today

  • Inspire Medical Systems (INSP) Slides as Recalls, Index Moves Raise Revenue Worries
    July 10, 2026, 6:04 AM EDT. Inspire Medical Systems (INSP) is back under investor pressure after product recalls and index changes, with Wall Street pricing in revenue pressure of 8%. Shares have clawed back 22.06% in the last 30 days but are still off 44.16% for the year and 63% over 12 months, signaling longer-term weakness. Analysts say the stock looks a bit undervalued now, with fair value at $52.17, just above the last close at $51.52. Near-term issues include onboarding delays for the Inspire V system and Medicare billing problems, all clouding the current growth view. Management expects these to resolve by the end of Q3, possibly turning revenue around in 2026. Still, the Street sees reimbursement and adoption risk, so investors weigh the valuation more cautiously now.
Go toTop